Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...

Bristol Myers’ $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company’s ongoing efficiency push.  | Bristol Myers' $1.5 billion restructuring initiative that ...

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis.

Bristol-Myers Squibb Co.’s stock rose 2.9% early Thursday, after the drug company posted better-than-expected third-quarter earnings and raised its guidance. Princeton, N.J.-based Bristol Myers had ...

Bristol-Myers Squibb (BMY) stock gained as the comany exceeded Q3 2024 financial forecasts, with strong revenue growth and ...

PRINCETON, N.J. — PRINCETON, N.J. — Bristol Myers Squibb Co. (BMY) on Thursday reported third-quarter profit of $1.21 billion. On a per-share basis, the Princeton, New Jersey-based company ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Coventry Police Department said a dog owner requested that their dog be killed because it had an aggressive temperament. It happened on Oct. 24. Investigators arrested Anthony Demitraszek as a ...

Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well-tolerated safety profile over 12 months across two Phase 3 trials.